Full Breakdown
White House Expands TrumpRx with New Drug Offerings
3/21/2026, 3:03:16 PM
Introduction of New Drugs
The White House announced on Friday the addition of three new medications to the TrumpRx self-pay platform, aiming to further its initiative to reduce prescription drug prices. The newly included drugs are Jentadueto and Jentadueto XR, both for Type 2 diabetes, and Striverdi Respimat, a treatment for chronic obstructive pulmonary disease (COPD). These medications, produced by the German pharmaceutical company Boehringer Ingelheim, are priced significantly lower on TrumpRx compared to their standard retail prices. For instance, Jentadueto, which typically costs around $525, is available on TrumpRx for approximately $55, while Striverdi Respimat is priced at about $35, down from roughly $276.
Pricing and Market Context
Ben Link, a contributor at the nonprofit organization 46brooklyn, noted that the discounts offered through TrumpRx are substantial. However, he also pointed out that patients often pay between $25 to $35 for the generic version of Jentadueto at pharmacies, suggesting that while TrumpRx prices are competitive, they may not always represent the lowest available options. The platform, which launched in January as part of President Donald Trump’s broader healthcare strategy, currently lists fewer than 60 drugs and primarily focuses on brand-name medications, many of which have cheaper generic alternatives.
Usage and Awareness Challenges
Despite the potential savings, the utilization of TrumpRx remains unclear. A recent survey by KFF indicated that awareness of the platform is relatively low, with only about one-third of prescription drug users having heard of it. Among those aware, just 7% reported visiting the site to compare prices, a figure that increased to 16% among users of GLP-1 medications. Chris Klomp, a senior official at the Department of Health and Human Services, emphasized that TrumpRx was designed as a limited cash-pay tool rather than a comprehensive solution for drug pricing issues.
Criticism and Limitations
The TrumpRx platform has faced criticism for its limited scope and the inability to use discounts in conjunction with insurance or to contribute toward deductibles. Klomp acknowledged that the initiative was not intended to serve as a widespread remedy for high drug costs, which continue to burden many Americans. A West Health-Gallup poll revealed that approximately one in three U.S. adults have made sacrifices to afford healthcare in the past year, including rationing or skipping medications.
Conclusion
As the ninth drugmaker to join the TrumpRx platform, Boehringer Ingelheim's inclusion reflects ongoing efforts to address healthcare costs. However, the platform's limitations and the low awareness among potential users highlight the challenges that remain in making prescription drugs more affordable for the American public.
